
Cell Metabolism, Journal Year: 2016, Volume and Issue: 23(4), P. 602 - 609
Published: March 10, 2016
Language: Английский
Cell Metabolism, Journal Year: 2016, Volume and Issue: 23(4), P. 602 - 609
Published: March 10, 2016
Language: Английский
Nature Reviews Endocrinology, Journal Year: 2016, Volume and Issue: 13(1), P. 26 - 35
Published: Sept. 12, 2016
Language: Английский
Citations
593Cell, Journal Year: 2015, Volume and Issue: 161(1), P. 146 - 160
Published: March 1, 2015
Language: Английский
Citations
444Nature Reviews Molecular Cell Biology, Journal Year: 2021, Volume and Issue: 22(6), P. 393 - 409
Published: March 23, 2021
Language: Английский
Citations
363Frontiers in Pharmacology, Journal Year: 2017, Volume and Issue: 8
Published: Sept. 25, 2017
Purinergic signalling, i.e. the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept not well accepted until early 1990's when receptor subtypes for purines and pyrimidines were cloned characterised, which includes 4 P1 (adenosine) receptor, 7 P2X ion channel receptors 8 P2Y G protein-coupled receptor. Early studies largely concerned with physiology, pharmacology biochemistry purinergic signalling. More recently, focus has been on pathophysiology therapeutic potential. There recognition use agonists treatment supraventicular tachycardia A2A antagonists are promising Parkinson's disease. Clopidogrel, a P2Y¬12 antagonist, is widely used thrombosis stroke, blocking receptor-mediated platelet aggregation. Diquafasol, long acting P2Y¬2 agonist, being dry eye. P2X3 have developed that orally bioavailable stable vivo currently clinical trials chronic cough, bladder incontinence, visceral pain hypertension. Antagonists to P2X7 investigated inflammatory disorders, including neurodegenerative diseases. Other investigations progress agents osteoporosis, myocardial infarction, irritable bowel syndrome, epilepsy, atherosclerosis, depression, autism, diabetes cancer.
Language: Английский
Citations
350Frontiers in Immunology, Journal Year: 2016, Volume and Issue: 7
Published: March 28, 2016
Within tumors, some areas are less oxygenated than others. Since their home ground is under chronic hypoxia, tumor cells adapt to this condition by activating aerobic glycolysis; however, hypoxic environment very harsh for incoming immune cells. Deprivation of oxygen limits availability energy sources and induces accumulation extracellular adenosine in tumors. Extracellular adenosine, upon binding with receptors on the surface various cells, suppresses pro-inflammatory activities. In addition, signaling through upregulates a number anti-inflammatory molecules immunoregulatory leading establishment long-lasting immunosuppressive environment. Thus, due hypoxia tumors can discourage antitumor responses no matter how response was induced, whether it spontaneous or artificially introduced therapeutic intention. Preclinical studies have shown significance survival strategy demonstrating regression after inactivation receptors, inhibition adenosine-producing enzymes, reversal tissue hypoxia. These promising results indicate potential use inhibitors hypoxia-adenosine pathway cancer immunotherapy.
Language: Английский
Citations
338Nature Metabolism, Journal Year: 2019, Volume and Issue: 1(2), P. 189 - 200
Published: Jan. 9, 2019
Language: Английский
Citations
308Cell, Journal Year: 2018, Volume and Issue: 174(6), P. 1571 - 1585.e11
Published: Sept. 1, 2018
Language: Английский
Citations
306Nature Reviews Endocrinology, Journal Year: 2017, Volume and Issue: 14(2), P. 77 - 87
Published: Oct. 20, 2017
Language: Английский
Citations
300Nature Reviews Drug Discovery, Journal Year: 2016, Volume and Issue: 15(6), P. 405 - 424
Published: March 11, 2016
Language: Английский
Citations
215Nutrition Reviews, Journal Year: 2018, Volume and Issue: 76(6), P. 395 - 417
Published: March 26, 2018
Type 2 diabetes (T2D) is a major health problem worldwide that associated with increased morbidity and mortality. There interest in the value of different nutrition-based strategies for preventing development T2D. This review aims to cover current knowledge regarding effects coffee consumption on T2D or modulation adverse complications. A meta-analysis risk was conducted. Moreover, bioactive components coffee, polymorphisms, potential underlying mechanism(s) relation complications are discussed. PubMed searched up December 1, 2017, prospective cohort nested case–control studies association between were selected. Two investigators independently extracted data from included studies. total 30 1 185 210 participants 53 018 incident cases meta-analysis. The pooled relative (RR) 0.71 (95% confidence interval [CI], 0.67–0.76) highest category (median consumption, 5 cups/d) vs lowest 0 cups/d). decreased by 6% (RR = 0.94; 95%CI, 0.93–0.95) each cup-per-day increase consumption. Results similar caffeinated (per additional cup per day: RR 0.93; 0.90–0.96) decaffeinated (corresponding 0.90–0.98). Available evidence indicates inversely Possible mechanisms behind this include thermogenic, antioxidative, anti-inflammatory effects; adenosine receptor signaling; microbiome content diversity.
Language: Английский
Citations
196